Clinical trial
Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients
NCT00055185 · Progenics Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00055185 |
|---|---|
| Title | Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients |
| Lead sponsor | Progenics Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Acquired Immune Deficiency Syndrome |
| Intervention type | Drug |
| Interventions | CD4-IgG2 (PRO 542) |
| Enrollment | 24 |
| Start date | Apr 1, 2003 |
| Completion | Jun 1, 2005 |
| First posted | Feb 21, 2003 |
| Last update posted | Oct 3, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: